TechInvention Lifecare has announced a strategic collaboration with Belgium-based Quantoom Biosciences. The Memorandum of Understanding (MoU) was formally signed during the Belgian Economic Mission to India recently.
As part of this collaboration, TechInvention is introducing Quantoom’s cutting-edge RNA manufacturing solutions to India with a strong focus on accessibility, scalability, and affordability. This advanced suite of technologies is designed to de-risk and accelerate the development of RNA-based vaccines.
Complementing this, TechInvention will leverage its translational research expertise, regulatory know-how, and GMP manufacturing capabilities to streamline developing, scaling, and commercialising novel RNA-based products.
This partnership represents a transformative milestone in India’s biotechnology landscape, establishing end-to-end mRNA production capabilities at TechInvention’s forthcoming EU-GMP-approved facility, the Global Collaborative Centre for Medical Countermeasures (GCMC), in Mumbai.
With a One Health approach, this collaboration extends beyond human health to encompass animal and environmental health. The technology is designed for environmental sustainability, integrating modular, low-carbon-footprint mRNA systems that support global decarbonization efforts. It aligns with worldwide initiatives to enable access to next-generation RNA technologies, ensuring that low- and middle-income countries (LMICs) benefit from locally manufactured, cost-effective, and scalable solutions.
This collaboration positions India as a hub for next-gen RNA-based vaccines, driving global partnerships for equitable healthcare.
